Overexpression of Cdc20 in clinically localized prostate cancer: Relation to high Gleason score and biochemical recurrence after laparoscopic radical prostatectomy

Cancer Biomarkers

Volumn 16, Issue 3, 2016, Pages 351-358

  Mao, Yunhua ^a   Li, Ke ^a   Lu, Li ^a   Si Tu, Jie ^a   Lu, Minhua ^a   Gao, Xin ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

biochemical recurrence; cell division cycle 20; Prostatic neoplasms; radical prostatectomy

Indexed keywords

CELL CYCLE PROTEIN 20; CDC20 PROTEIN, HUMAN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BIOCHEMICAL RECURRENCE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CONTROLLED STUDY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LAPAROSCOPIC SURGERY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROTEIN EXPRESSION; SEMINAL VESICLE; TRANSURETHRAL RESECTION; TUMOR INVASION; BIOSYNTHESIS; BLOOD; CANCER GRADING; LAPAROSCOPY; MIDDLE AGED; PATHOLOGY; PROSTATE; PROSTATE TUMOR; TUMOR RECURRENCE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CDC20 PROTEINS; HUMANS; LAPAROSCOPY; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

EID: 84964240557     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-160573     Document Type: Article

References (33)

1. R. Siegel, J. Ma, Z. Zou and A. Jemal. Cancer statistics, 2014, CA Cancer J Clin 64 (2014), 9-29
2. C.L. Amling. Biochemical recurrence after localized treatment, Urol Clin North Am 33 (2006), 147-59, v
3. D.I. Quinn, S.M. Henshall, A.M. Haynes, P.C. Brenner, R. Kooner, D. Golovsky, J. Mathews, G.F. O?Neill, J.J. Turner, W. Delprado, J.F. Finlayson, R.L. Sutherland, J.J. Grygiel and P.D. Stricker, Prognostic significance of pathologic features in localized prostate cancer treated with radical prostatectomy: implications for staging systems and predictive models, J Clin Oncol 19 (2001), 3692-705
4. E.S. Spencer, R.B. Johnston, R.R. Gordon, J.M. Luca, C.H. Ussakli, A. Hurtado-Coll, S. Srivastava, P.S. Nelson and C.R. Porter, Prognostic value of ERG oncoprotein in prostate cancer recurrence and cause-specific mortality, Prostate 73 (2013), 905-12
5. M.W. Kattan, C. Yu, L. Salomon, K. Vora, K. Touijer and B. Guillonneau, Development and validation of preoperative nomogram for disease recurrence within 5 years after laparoscopic radical prostatectomy for prostate cancer, Urology 77 (2011), 396-401
6. S. Punnen, S.J. Freedland, J.C. Presti, Jr., W.J. Aronson, M.K. Terris, C.J. Kane, C.L. Amling, P.R. Carroll andM.R. Cooperberg, Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy, Eur Urol 65 (2014), 1171-7
7. A.C. Mackinnon, B.C. Yan, L.J. Joseph and H.A. Al-Ahmadie. Molecular biology underlying the clinical heterogeneity of prostate cancer: an update, Arch Pathol Lab Med 133 (2009), 1033-40
8. M.A. Tapia-Laliena, N. Korzeniewski, M. Hohenfellner and S. Duensing, High-risk prostate cancer: a disease of genomic instability, Urol Oncol 32 (2014), 1101-7
9. G.J. Kops, B.A. Weaver and D.W. Cleveland, On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 5 (2005), 773-85
10. R. Bharadwaj and H. Yu, The spindle checkpoint, aneuploidy, and cancer. Oncogene 23 (2004), 2016-27
11. S. Kim and H. Yu, Mutual regulation between the spindle checkpoint and APC/C. Semin Cell Dev Biol 22 (2011), 551-8
12. P. Silva, J. Barbosa, A.V. Nascimento, J. Faria, R. Reis and H. Bousbaa, Monitoring the fidelity of mitotic chromosome segregation by the spindle assembly checkpoint. Cell Prolif 44 (2011), 391-400
13. J. Weinstein, F.W. Jacobsen, J. Hsu-Chen, T. Wu and L.G. Baum, A novel mammalian protein, p55CDC, present in dividing cells is associated with protein kinase activity and has homology to the Saccharomyces cerevisiae cell division cycle proteins Cdc20 and Cdc4. Mol Cell Biol 14 (1994), 3350-63
14. H. Yu, Cdc20: A WD40 activator for a cell cycle degradation machine. Mol Cell 27 (2007), 3-16
15. H. Rajagopalan and C. Lengauer, Aneuploidy and cancer. Nature 432 (2004), 338-41
16. D.Z. Chang, Y. Ma, B. Ji, Y. Liu, P. Hwu, J.L. Abbruzzese, C. Logsdon and H. Wang, Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression, J Hematol Oncol 5 (2012), 15
17. G. Mondal, S. Sengupta, C.K. Panda, S.M. Gollin, W.S. Saunders and S. Roychoudhury, Overexpression of Cdc20 leads to impairment of the spindle assembly checkpoint and aneuploidization in oral cancer, Carcinogenesis 28 (2007), 81-92
18. I.M. Moura, M.L. Delgado, P.M. Silva, C.A. Lopes, J.B. do Amaral, L.S.Monteiro and H. Bousbaa, High CDC20 expression is associated with poor prognosis in oral squamous cell carcinoma, J Oral Pathol Med 43 (2014), 225-31
19. J.W. Choi, Y. Kim, J.H. Lee and Y.S. Kim, High expression of spindle assembly checkpoint proteins CDC20 and MAD2 is associated with poor prognosis in urothelial bladder cancer, Virchows Arch 463 (2013), 681-7
20. T. Kato, Y. Daigo, M. Aragaki, K. Ishikawa, M. Sato and M. Kaji, Overexpression of CDC20 predicts poor prognosis in primary non-small cell lung cancer patients, J Surg Oncol 106 (2012), 423-30
21. Y.Kim, J.W.Choi, J.H. Lee andY.S. Kim, MAD2 andCDC20 are upregulated in high-grade squamous intraepithelial lesions and squamous cell carcinomas of the uterine cervix. Int J Gynecol Pathol 33 (2014), 517-23
22. H. Karra, H. Repo, I. Ahonen, E. Loyttyniemi, R. Pitkanen, M. Lintunen, T. Kuopio, M. Soderstrom and P. Kronqvist, Cdc20 and securin overexpression predict short-Term breast cancer survival, Br J Cancer 110 (2014), 2905-13
23. F. Mertens, B. Johansson and F. Mitelman, Isochromosomes in neoplasia, Genes Chromosomes Cancer 10 (1994), 221-30
24. F. Uhlmann, D. Wernic, M.A. Poupart, E.V. Koonin and K. Nasmyth, Cleavage of cohesin by the CD clan protease separin triggers anaphase in yeast. Cell 103 (2000), 375-86
25. M. Li, X. Fang, Z.Wei, J.P.York and P. Zhang, Loss of spindle assembly checkpoint-mediated inhibition of Cdc20 promotes tumorigenesis in mice. J Cell Biol 185 (2009), 983-94
26. T. Kidokoro, C. Tanikawa, Y. Furukawa, T. Katagiri, Y. Nakamura and K. Matsuda, CDC20, a potential cancer therapeutic target, is negatively regulated by p53. Oncogene 27 (2008), 1562-71
27. T. Banerjee, S. Nath and S. Roychoudhury, DNA damage induced p53 downregulates Cdc20 by direct binding to its promoter causing chromatin remodeling, Nucleic Acids Res 37 (2009), 2688-98
28. S. Yamanaka, N.R. Campbell, F. An, S.C. Kuo, J.J. Potter, E. Mezey, A. Maitra and F.M. Selaru, Coordinated effects of microRNA-494 induce G(2)/M arrest in human cholangiocarcinoma. Cell Cycle 11 (2012), 2729-38
29. H.B. Sun, X. Chen, H. Ji, T. Wu, H.W. Lu, Y. Zhang, H. Li and Y.M. Li, miR494 is an independent prognostic factor and promotes cell migration and invasion in colorectal cancer by directly targeting PTEN. Int J Oncol 45 (2014), 2486-94
30. W.J. Wu, K.S. Hu, D.S. Wang, Z.L. Zeng, D.S. Zhang, D.L. Chen, L. Bai and R.H. Xu, CDC20 overexpression predicts a poor prognosis for patients with colorectal cancer, J Transl Med 11 (2013), 142
31. M. Lize, C. Herr, A. Klimke, R. Bals and M. Dobbelstein, MicroRNA-449a levels increase by several orders of magnitude during mucociliary differentiation of airway epithelia. Cell Cycle 9 (2010), 4579-83
32. M. Kang, C.W. Jeong, W.S. Choi, Y.H. Park, S.Y. Cho, S. Lee, S.B. Lee, J.H. Ku, S.K. Hong, S.S. Byun, H. Jeong, C. Kwak, H.H. Kim, E. Lee and S.E. Lee, Pre-And post-operative nomograms to predict recurrence-free probability in korean men with clinically localized prostate cancer. PLoS OnE 9 (2014), e100053
33. H. Isbarn, M. Wanner, G. Salomon, T. Steuber, T. Schlomm, J. Kollermann, G. Sauter, A. Haese, H. Heinzer, H. Huland and M. Graefen, Long-Term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen era, BJU Int 106 (2010), 37-43